GVR Report cover Oncology Based In-vivo CRO Market Size, Share & Trends Report

Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumor), By Model (Syngeneic Model, Patient Derived Xenograft (PDX), Xenograft), By Region, And Segment Forecasts, 2021 - 2028

  • Published Date: Aug, 2021
  • Base Year for Estimate: 2020
  • Report ID: GVR-1-68038-859-6
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2019
  • Number of Pages: 90

Report Overview

The global oncology based in-vivo CRO market size was valued at USD 995.5 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 8.2% from 2021 to 2028. The increasing frequency of outsourcing of R&D activities by major pharmaceutical companies to focus on their core competencies is a high-impact-rendering driver for market growth. Furthermore, the economic efficiency offered by CROs rather than conducting an in-house study is likely to boost their demand over the forecast period.

U.S. oncology based in-vivo CRO market size, by indication, 2018 - 2028 (USD Million)

The oncology based in-vivo CRO activities were heavily disrupted in 2020 owing to the repercussions of the COVID-19 pandemic. As of 29 July 2021, there are over 196,723,561 COVID-19 cases resulting in more than 4,203,952 deaths across the globe. Several clinical trials were delayed owing to the ongoing pandemic. Cancer patients are vulnerable to COVID and are at high risk for contracting severe consequences from the disease. According to the International Agency for Research on Cancer (IARC) the global cancer burden is of over 19.3 million cases in 2020.

The challenge in front of healthcare providers is to limit exposure of their patients and patients’ caregivers to COVID patients as well as asymptomatic carriers while continuing to ensure access to clinical trials. However, the future seems good for the market with the emergence of telehealth and virtual clinical trials. Such technologies allow CRO activities while ensuring the safety of cancer patients. Furthermore, regulatory bodies such as the U.S. FDA have issued guidance and developed new policies to cope up with the current scenario and solve the problem of bottlenecked clinical trials.

The present business scenario is witnessing rapid changes in the marketplace and consumer preferences are pushing the players to innovate and generate better-performing products at a faster rate to sustain. CROs have developed their products and services such that they help manufacturers in gaining momentum with their R&D processes and overcoming any hurdles that they may face. Owing to their proficiency and years of experience in the business, they perform the given tasks at an exceptionally fast speed. According to a survey conducted by Tufts Center for the Study of Drug Development (CSDD), among the top management of the major pharmaceutical companies, more than 75.0% of executives said that CROs are more time-efficient in comparison to the internal teams, thereby increasing the need for outsourcing.

Pharmaceutical organizations are increasingly outsourcing R&D activities to CROs to stay competitive and flexible in the world of growing knowledge, gradually sophisticated technologies, and unstable economic environment. The tasks that companies prefer to outsource include a wide range of activities from basic research to late-stage development such as target validation, hit exploration and lead optimization, genetic engineering, assay development safety, and efficacy tests in animal models as well as clinical trials involving humans.

Indication Insights

The solid tumors dominated the market for oncology based in-vivo CRO and accounted for the largest revenue share of 46.5% in 2020. The factors responsible for higher research in the field of solid tumors are the presence of over 800 new molecules that are under pipeline by large pharmaceutical companies, availability of grants from institutes such as NIH and NCI, and the existing gap between demand and supply of therapeutic treatments for solid cancer.

Solid tumors are cancer occurring within organs, muscles, or bones. These are generally addressed as carcinomas and sarcomas. The increasing incidence of cancer across the globe and growing interest of world agencies such as the WHO in analyzing their prevalence, causative agents, and treatment options are boosting the R&D. For instance, BioInvent, a Swedish CRO is currently performing multiple preclinical oncology research in collaboration with players such as Bayer Healthcare, Daiichi Sankyo, and Servier.

Regional Insights

North America dominated the oncology based in-vivo CRO market and accounted for the largest revenue share of 49.6% in 2020. This can be attributed to the presence of technologically advanced CROs present in this region. The U.S. has the highest per capita healthcare spending and the availability of funding and grants from government organizations such as the National Institute of Health (NIH) fosters research activities. The trend for reducing the R&D cost level is most common in major life sciences companies. Clinical trial sponsors are facing huge pressure owing to the increasing complexity in the research methodology to reduce time and cost. The increasing R&D activities and need to reduce the overall trial expenditure are expected to drive the need for CROs in North America.

Global oncology based in-vivo CRO market share, by region, 2020 (%)

On the other hand, Asia Pacific is projected to exhibit lucrative growth in the market for oncology based in-vivo CRO over the forecast period. The presence of untapped opportunities, constantly improving healthcare infrastructure, economic development, and huge patient base are some factors responsible for the rapid growth. This region also ranks on top in ease of doing business. Moreover, with the availability of qualified labor and other resources, Asia Pacific would be the key destination for in-vivo CRO projects over the forecast period.

Key Companies & Market Share Insights

The augmenting rate at which outsourcing of activities is growing within the healthcare industry results in the entry of various new players coupled with collaborative efforts by existing players is expected to be witnessed over the forecast period. For instance, in January 2020, Charles River Laboratories collaborated with Takeda Pharmaceutical Company to identify & develop preclinical candidates and acquired HemaCare Corporation for USD 380.0 million. HemaCare Corporation is likely to become a part of the company’s research models and services segment. Some of the prominent players in the oncology based in-vivo CRO market include:

  • Charles River Laboratory

  • ICON Plc

  • Covance

  • Eurofins Scientific

  • Taconic Biosciences

  • Crown Bioscience

  • Toxikon, Inc.

  • WuXi AppTec

  • EVOTEC

  • The Jackson Laboratory

Oncology Based In-vivo CRO Market Report Scope

Report Attribute

Details

Market size value in 2021

USD 1.1 billion

Revenue forecast in 2028

USD 1.9 billion

Growth Rate

CAGR of 8.2% from 2021 to 2028

Base year for estimation

2020

Historical data

2016 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Indication, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; China; Japan; Argentina; Brazil; South Africa; Saudi Arabia,

Key companies profiled

Charles River Laboratory; ICON Plc; Covance; Eurofins Scientific; Taconic Biosciences; Crown Bioscience; Toxikon, Inc.; WuXi AppTec; EVOTEC; The Jackson Laboratory

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global oncology based in-vivo CRO market report on the basis of indication and region:

  • Indication Outlook (Revenue, USD Million, 2016 - 2028)

    • Blood cancer

      • Syngeneic model

      • Patient Derived Xenograft (PDX)

      • Xenograft

    • Solid tumors

      • Syngeneic model

      • Patient Derived Xenograft (PDX)

      • Xenograft

    • Others

      • Syngeneic model

      • Patient Derived Xenograft (PDX)

      • Xenograft

  • Regional Outlook (Revenue, USD Million, 2016 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

    • Asia Pacific

      • Japan

      • China

    • Latin America

      • Brazil

      • Argentina

    • Middle East and Africa (MEA)

      • South Africa

      • Saudi Arabia

Frequently Asked Questions About This Report

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.